Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial

Eleonora Riccio, Massimo Sabbatini, Dario Bruzzese, Ivana Capuano, Silvia Migliaccio, Michele Andreucci, Antonio Pisani, Eleonora Riccio, Massimo Sabbatini, Dario Bruzzese, Ivana Capuano, Silvia Migliaccio, Michele Andreucci, Antonio Pisani

Abstract

Background: Recent studies suggest that vitamin D deficiency represents an additional cofactor of renal anemia, with several mechanisms accounting for this relationship. In line with it, the administration of vitamin D or its analogues has been associated with an improvement of anemia. There are no data, however, about a direct effect of paricalcitol on hemoglobin (Hb) levels. Therefore, we conducted a study to determine whether paricalcitol, compared to calcitriol, improves anemia in patients with chronic kidney disease (CKD).

Methods: In this randomized trial 60 CKD patients stage 3b-5 and anemia (Hb levels: 10-12.5 g/dL) were assigned (1:1) to receive low doses of calcitriol (Group Calcitriol) or paricalcitol (Group Paricalcitol) for 6 months. All the patients had normal values of plasma calcium, phosphorus and PTH, a stable iron balance, and normal values of C-Reactive Protein. The primary endpoint was to evaluate the effects of the two treatments on Hb levels; the modifications in 24hr-proteinuria (UProt) were also evaluated.

Results: A significant Group x Time interaction effect was observed in the longitudinal analysis of Hb levels (F(1,172)=31.4, p<0.001). Subjects in Paricalcitol experienced a significant monthly increase of Hb levels equal to +0.16 g/dL [95% C.I. 0.10 to +0.22, p<0.001) while in Group Calcitriol, Hb decrease throughout the follow-up with an average monthly rate of -0.10 g/dL (95% C.I.: -0.17 to -0.04, p<0.001). In Group Paricalcitol, UProt was significantly reduced after 6 months [0.35 (0.1-1.2) vs 0.59 (0.2-1.6), p<0.01], whereas no significant difference emerged in Group Calcitriol. Plasma levels of calcium, phosphate, PTH and of inflammation markers remained in the normal range in both groups throughout the study.

Conclusions: Short-term exposure to paricalcitol results in an independent increase in Hb levels, which occurred with no modification of iron balance, inflammatory markers, and PTH plasma concentrations, and was associated with a decrease in UProt.

Trial registration: ClinicalTrials.gov NCT01768351.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Flow chart of patient selection.
Fig 1. Flow chart of patient selection.
Fig 2. Effects of calcitriol (Group Calcitriol,…
Fig 2. Effects of calcitriol (Group Calcitriol, dashed lines) and paricalcitol (Group Paricalcitol, solid lines) on hemoglobin plasma levels throughout the study.
Data are expressed as means ± SD. Abbreviations: T0, baseline levels; T2, T4 and T6, values after 2, 4 and 6 months of follow-up with both drugs. * = p

Fig 3. Effects of calcitriol (Group Calcitriol,…

Fig 3. Effects of calcitriol (Group Calcitriol, dashed lines) and paricalcitol (Group Paricalcitol, solid lines)…

Fig 3. Effects of calcitriol (Group Calcitriol, dashed lines) and paricalcitol (Group Paricalcitol, solid lines) on urinary protein excretion/GFR ratio throughout the study.
Data are expressed as means ± SE. Abbreviations: T0, baseline levels; T2, T4 and T6, values after 2, 4 and 6 months of follow-up with both drugs.
Fig 3. Effects of calcitriol (Group Calcitriol,…
Fig 3. Effects of calcitriol (Group Calcitriol, dashed lines) and paricalcitol (Group Paricalcitol, solid lines) on urinary protein excretion/GFR ratio throughout the study.
Data are expressed as means ± SE. Abbreviations: T0, baseline levels; T2, T4 and T6, values after 2, 4 and 6 months of follow-up with both drugs.

References

    1. Lin R, White JH. The pleiotropic effects of Vitamin D. BioEssays 2003; 26: 21–28.
    1. Nagpal S, Na SN, Rathrachelam R. Noncalcemic actions of Vitamin D Receptor ligands. Endocr Rev 2005; 26: 662–687.
    1. Li YC, Kong J, Wei M, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110: 228–238.
    1. Gravellone L, Rizzo MA, Martina V, Mezzina N, Regalia A, Gallieni M. Vitamin D receptor activators and clinical outcomes in chronic kidney disease. Int J Nephrol 2011; 2011: 419524 10.4061/2011/419524
    1. Lee JH O’Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency, an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol 2008; 52: 1949–1956.
    1. Andress DL. Vitamin D in chronic kidney disease. Best Pract Res Clin Endocrinol Metab 2011; 25: 647–655. 10.1016/j.beem.2011.05.005
    1. Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency and inflammation and their association with hemoglobin levels in chronic kidney disease. Am J Nephrol 2009; 30: 64–72. 10.1159/000202632
    1. Patel NM, Gutiérrez OM, Andress DL, Coyne DW, Levin A, Wolf M. Vitamin D deficiency and anemia in early chronic kidney disease. Kidney Int 2010; 77: 715–720. 10.1038/ki.2009.551
    1. Sim JJ, Lac PT, Liu IL, Kumar VA, Kujubu DA, Rasgon SA. Vitamin D deficiency and anemia: a cross-sectional study. Ann Hematol 2010; 89: 447–452. 10.1007/s00277-009-0850-3
    1. Meguro S, Tomita M, Katsuki T, Kato K, Oh H, Ainai A, et al. Plasma 25-hydroxyvitamin D is independently associated with hemoglobin concentration in male subjects with type 2 diabetes mellitus. Int J Endocrinol 2011; 2011: 362981 10.1155/2011/362981
    1. Alon DB, Chaimovitz C, Dvilansky A, Lugassy G, Douvdevani A, Shany S, et al. Novel role of 1,25(OH)(2)D(3) in induction of erythroid progenitor cell proliferation. Exp Hematol 2002; 30: 403–409.
    1. Aucella F, Scalzulli RP, Gatta G, Vigilante M, Carella AM, Stallone C. Calcitriol increases burst-forming unit-erythroid proliferation in chronic renal failure. A synergistic effect with r-HuEPO. Nephron Clin Pract 2003; 95: c121–c127.
    1. Keithi-Reddy SR, Addabbo F, Patel TV, Mittal BV, Goligorsky MS, Singh AK. Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int 2008; 74: 782–790. 10.1038/ki.2008.245
    1. Icardi A, Paoletti E, De Nicola L, Mazzaferro S, Russo R, Cozzolino M. Renal anemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. Nephrol Dial Transplant 2013; 28: 1672–1679. 10.1093/ndt/gft021
    1. Baeke, Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006; 69: 33–43.
    1. Brancaccio D, Cozzolino M, Gallieni M. Hyperparathyroidism and anemia in uremic subjects: a combined therapeutic approach. J Am Soc Nephrol 2004; 15(Suppl. 1): S21–S24.
    1. Albitar S, Genin M, Fen-Chong M, Serveaux MO, Schohn D, Chuet C. High dose alfacalcidol improves anemia in patients on hemodialysis. Nephrol Dial Transplant 1997; 12: 514–518.
    1. Saab G, Young DO, Gincherman Y, Giles K, Norwood K, Coyne DW. Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 2007; 105: C132–C138.
    1. Goicoecheca M, Vazquez MI, Ruiz Ma, Gomez-Campdera F, Perez-García R, Valderrábano F. Intravenous calcitriol improves anemia and reduces the need for erythropoietin in haemodialysis patients. Nephron 1998; 78: 23–27.
    1. Capuano A, Serio V, Pota A, Memoli B, Andreucci VE. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients. J Nephrol 2009; 22: 59–68.
    1. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427–1432.
    1. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483–1490.
    1. Monier-Faugere MC, Mawad H, Maaluche FF. Opposite effects of Calcitriol and Paricalcitol on the parathyroid hormone-(1–84)/large carboxy-terminal-parathyroid hormone fragments ratio in patients with stage 5 chronic kidney disease. Clin J Am Soc Nephrol 2007; 2: 1255–1260.
    1. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 52: 249–255.
    1. Guerrero F, Montes de Oca A, Aguilera-Tejero E, Zafra R, Rodríguez M, López I. The effect of vitamin D derivatives on vascular calcification associated with inflammation. Nephrol Dial Transplant 2012; 27: 2206–2212. 10.1093/ndt/gfr555
    1. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823–2828.
    1. Bertoli M, Luisetto G, Ruffatti A, Urso M, Romagnoli G. Renal function during calcitriol therapy in chronic renal failure. Clin Nephrol 1990; 33: 98–102.
    1. Perez A, Raab R, Chen TC, Turner A, Holick MF. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 1996; 134: 1070–78.
    1. Kuhlman A, Haas CS, Gross ML, Reulbach U, Holzinger M, Schwarz U, et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286: F526–F533.
    1. Matsui I, Hamano T, Tomida K, Inoue K, Takabatake Y, Nagasawa Y, et al. Active vitamin D and its analogue, 22-oxacalcitriol, ameliotare puromycin aminonucleoside-induced nephrosis in rats. Nephrol Dial Transplant 2009; 24: 2354–2361. 10.1093/ndt/gfp117
    1. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009; 54: 647–652. 10.1053/j.ajkd.2009.04.036
    1. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543–1551. 10.1016/S0140-6736(10)61032-X
    1. Bárány P. Inflammation, serum C-reactive protein, and erythropoietin resistance. Nephrol Dial Transplant 2001; 16: 224–227.
    1. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33: 63–72.
    1. Del Vecchio L, Pozzoni P, Andrulli S, Locatelli F. Inflammation and resistance to treatment with recombinant human erythropoietin. J Ren Nutr 2005;15: 137–141.
    1. Rathaus M. C-reactive protein in the assessment of iron status in patients on hemodialysis. G Ital Nefrol 2009; 26: 338–346;
    1. Marckmann P, Agerskov H, Thineshkumar S, Bladbjerg EM, Sidelmann JJ, Jespersen J, et al. Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D. Nephrol Dial Transplant 2012; 27: 3523–3531. 10.1093/ndt/gfs138

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit